Clinical trials: CIS
Bladder Carcinoma in Situ (CIS)
Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)
This is a phase III, single-arm, multicenter, international study to assess the efficacy and safety of ONCOFID-P-B following intravesical instillation in adult patients with histologically and cytologically confirmed CIS, with or…
- Trial name
- NCT05024773
- Testing
- ONCOFID P-B (PACLITAXEL-HYALURONIC ACID)
- Where
- 47 sites in United States, France and 4 more
- Volunteers
- 130 people
- Sponsor
- Fidia Farmaceutici s.p.a.
Breast Cancer - Ductal Carcinoma in Situ (DCIS), Breast-Conserving Surgery
Reoperation Rate in Breast-Conserving Surgery Using Confocal Histolog® Scanner for Intraoperative Margin Assessment
This PMPF study is proposed to evaluate in real life the reoperation rates (ROR) of breast cancer and/or DCIS surgery when including the use of the HLS in the context of breast lumpectomy margin assessment.
- Trial name
- SHIELD (NCT05946759)
- Testing
- Histolog Scanner
- Where
- Germany
- Volunteers
- 54 people
- Sponsor
- SamanTree Medical SA
Multiple Sclerosis, Clinically Isolated System
Betaferon® Regulatory Post-Marketing Surveillance
To identify problems/questions about following items in the clinical practice using Betaferon 1. Unknown adverse event (especially serious adverse event) 2. Identification of adverse event occurred in the real practice 3.
- Trial name
- NCT01414816
- Testing
- Interferon beta-1b (Betaseron, BAY86-5046)
- Where
- South Korea
- Volunteers
- 355 people
- Sponsor
- Bayer
Multiple Sclerosis
BAY86-5046 (Betaseron), Non Interventional Studies
This study aims to investigate adherence to therapy among patients treated with Betaferon who are using the BETACONNECT autoinjector.
- Trial name
- BETAEVAL (NCT02121444)
- Testing
- Interferon beta-1b (Betaferon, BAY 86-5046), BETACONNECT auto-injector.
- Where
- Germany
- Volunteers
- 151 people
- Sponsor
- Bayer
Non-Melanoma Skin Cancers
A Trial to Study the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratoses and Non-Melanoma Skin Cancers
Open-Label study evaluating safety and efficacy of SM-020 Gel 1.0% in subjects with Seborrheic Keratoses and Non-Melanoma Skin Cancers (i.e. Basal Cell Carcinoma and Squamous Cell Carcinoma In Situ).
- Trial name
- NCT06409195
- Testing
- SM-020 1% Gel
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- DermBiont, Inc.
Relapsing Multiple Sclerosis
A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis
A single arm study evaluating the continued efficacy, safety and tolerability of ofatumumab in patients with relapsing multiple sclerosis who are transitioning from aCD20 mAb therapy
- Trial name
- OLIKOS (NCT04486716)
- Testing
- Ofatumumab
- Where
- 20 sites in United States, Puerto Rico
- Volunteers
- 111 people
- Sponsor
- Novartis Pharmaceuticals